Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 20 Issue: 4, April 2020

Meet Our Executive Guest Editor free to download

Volume:20   Issue: 4
Pp: 239-239
C. Xu
DOI: 10.2174/156800962004200430123432
Published on: 30 April, 2020

Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation

Volume:20   Issue: 4
Pp: 240-252
Miriana Cardano, Carla Tribioli and Ennio Prosperi*
DOI: 10.2174/1568009620666200115162814
Published on: 15 January, 2020

Old and New Approaches to Target the Hsp90 Chaperone

Volume:20   Issue: 4
Pp: 253-270
Jackee Sanchez, Trever R. Carter, Mark S. Cohen* and Brian S.J. Blagg
DOI: 10.2174/1568009619666191202101330
Published on: 01 December, 2019

Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications

Volume:20   Issue: 4
Pp: 271-287
Kuldeep Rajpoot*
DOI: 10.2174/1568009620666200115160805
Published on: 15 January, 2020

circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma

Volume:20   Issue: 4
Pp: 288-294
Xinyu Tan, Duxun Tan, Haomiao Li, Ye Lin, Zhishen Wen and Canjun Zeng*
DOI: 10.2174/1568009619666191107140948
Published on: 07 November, 2019

In Vitro Investigation Demonstrates IGFR/VEGFR Receptor Cross Talk and Potential of Combined Inhibition in Pediatric Central Nervous System Atypical Teratoid Rhabdoid Tumors

Volume:20   Issue: 4
Pp: 295-305
Halah Obaid, Sunand Kannappan, Mehul Gupta, Yibing Ruan, Chunfen Zhang, Pinaki Bose* and Aru Narendran*
DOI: 10.2174/1568009619666191111153049
Published on: 11 November, 2019

Disintegrin Tablysin-15 Suppresses Cancer Hallmarks in Melanoma Cells by Blocking FAK/Akt/ERK and NF-κB Signaling

Volume:20   Issue: 4
Pp: 306-315
Zhenhui Deng, Qingye Zeng, Jinwei Chai, Bei Zhang, Wenhong Zheng, Xueqing Xu* and Jiguo Wu*
DOI: 10.2174/1568009620666200101094736
Published on: 31 December, 2019